Desperate lung cancer patients get access to experimental drug
NCT ID NCT04741789
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers capmatinib, an oral drug, to people with advanced non-small cell lung cancer who have no other treatment options and cannot join a clinical trial. It is a managed access (compassionate use) program, not a formal study. The goal is to provide potential benefit when no satisfactory alternative exists.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Capmatinib (also known as INC280), a tablet taken by mouth
- What this could lead to
- If successful, this program could provide a treatment option for people with advanced lung cancer who have run out of standard therapies.
- What could go wrong
- This is not a clinical trial testing effectiveness; it is a compassionate-use program. Results may vary, and risks are not fully studied in this setting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a targeted pill keep lung cancer from returning?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?